Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report

What the coverage shows

Both outlets frame the story as Merck and Moderna reporting results on an experimental melanoma vaccine, with the New York Times using the broader recurrence-focused headline and Ars Technica highlighting the companies’ claim of a 42% cut in death and recurrence. The Ars Technica extract is the only one that mentions top-line results and says the trial had already been reported as successful.

Written by Crossfiled from the 2 headlines and extracts below, not from the articles themselves. It describes how the outlets framed this, not what happened. Open any headline for a summary of that article.